UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC., Petitioner

v.

NOVO NORDISK A/S, PATENT OWNER

CASE IPR2024-00631 U.S. PATENT NO. 10,335,462 ISSUED: JULY 2, 2019

TITLE: USE OF LONG-ACTING GLP-1 PEPTIDES

DECLARATION OF HUGH DAVID CHARLES SMYTH, Ph.D.

March 1, 2024




TABLE OF CONTENTS

-		Page								
TABLE OF CONTENTS i										
TABLE OF ABBREVIATIONSv										
I.	QUALIFICATIONS AND BACKGROUND									
	A.	Education and Experience1								
	В.	Basis for Opinions and Materials Considered5								
	C.	Retention and Compensation								
II.	SUM	IMARY OF OPINIONS6								
III.	LEG	AL STANDARDS7								
IV.	PER	PERSON OF ORDINARY SKILL IN THE ART9								
V.	THE '462 PATENT (Ex.1001)									
	A.	The Formulation Claims of the '462 Patent11								
	B.	The Prosecution History of the '462 Patent								
VI.	CLA	IM CONSTRUCTION15								
VII.		BACKGROUND ON GLP-1 COMPOUND FORMULATIONS USED TO TREAT DIABETES16								
	A.	Parenteral formulations and components thereof were well- known								
	B.	GLP-1 compounds were well-known17								
	C.	GLP-1 agonists and related formulations were well-known20								
	D.	Parenteral dosage forms for peptide-based drugs21								
		1. Tonicity and osmolarity of the parenteral formulation23								
		2. pH and buffering capacity of the parenteral formulation24								
		3. Avoiding particulates in the parenteral formulation25								
		4. Vehicles and diluents of the parenteral formulation26								
		5. Excipients of the parenteral formulation27								
VIII. SCOPE AND CONTENT OF THE PRIOR ART										
	A.	WO 2011/138421 ("WO421") (Ex.1011)								

	B.	U.S. Patent Application Pub. No. US2007/0010424 ('424 publication) (Ex.1016)				
	C.	Clinio	cal Trial No. NCT00696657 (NCT657) (Ex.1013)32			
	D.	Clinic	cal Trial No. NCT00851773 (NCT773) (Ex.1014)34			
	E.	WO 2	2006/097537 ("WO537") (Ex.1015)			
	F.	Lovsl	nin (Ex.1012)			
	G.	Other	Art That Informs the POSA's Knowledge40			
		1.	Lund (Ex.1035)40			
		2.	U.S. Patent No. 7,022,674 ("'674 patent") (Ex.1075)42			
3.			U.S. Patent No. 6,458,924 ("'924 patent") (Ex.1073)44			
		4.	U.S. Patent No. 6,284,727 ("727 patent") (Ex.1071)45			
		5.	U.S. Patent No. 6,268,343 ("Knudsen patent") (Ex.1034)45			
		6.	U.S. Patent No. 5,512,549 ("'549 patent") (Ex.1017)47			
		7.	U.S. Patent No. 5,164,366 ("'366 patent") (Ex.1072)48			
		8.	U.S. Patent No. 5,118,666 ("'666 patent") (Ex.1056)48			
		9.	Victoza label (Ex.1039)49			
		10.	WO 03/002136 ("WO136") (Ex.1041)			
		11.	WO 00/37098 ("WO098") (Ex.1074)			
		12.	Additional prior art and references			
IX.			TABILITY OF THE CLAIMS OF THE '462			
	A.	nds 3 and 5: Claims 4-10 of the '462 patent would have obvious over WO421 considering the '424 publication or NCT657 and NCT773 considering the '424 publication53				
	A POSA would have been motivated to formulate semaglutide as an isotonic aqueous solution for subcutaneous injection with a reasonable expectation of success					
		2.	A POSA would have been motivated to formulate semaglutide with propylene glycol and phenol with a reasonable expectation of success			

3.	A POSA would have been motivated to formulate semaglutide with a phosphate buffer, such as sodium dihydrogen phosphate, with a reasonable expectation of success
4.	A POSA would have been motivated to formulate semaglutide with a pH in the range of 7.0-9.0, or at a pH of 7.4, with a reasonable expectation of success
5.	The dependent limitations of claim 4 would have been obvious
6.	The dependent limitations of claim 5 would have been obvious
7.	The dependent limitations of claim 6 would have been obvious
8.	The dependent limitations of claim 7 would have been obvious
9.	The dependent limitations of claim 8 would have been obvious
10.	The dependent limitations of claim 9 would have been obvious
11.	The dependent limitations of claim 10 would have been obvious
12.	Conclusion83
	nd 4: Claims 4-10 of the '462 patent would have been us over WO537 considering Lovshin
1.	A POSA would have been motivated to formulate semaglutide as an isotonic aqueous solution for subcutaneous injection with a reasonable expectation of success
2.	A POSA would have been motivated to formulate semaglutide with propylene glycol and phenol with a reasonable expectation of success
3.	A POSA would have been motivated to formulate semaglutide with a phosphate buffer, such as sodium

B.

			dihydrogen phosphate, with a reasonable expectation of success	89
		4.	A POSA would have been motivated to formulate semaglutide with a pH in the range of 7.0-9.0, or at a pH of 7.4, with a reasonable expectation of success	91
		5.	The dependent limitations of claim 4 would have been obvious	92
		6.	The dependent limitations of claim 5 would have been obvious	94
		7.	The dependent limitations of claim 6 would have been obvious	95
		8.	The dependent limitations of claim 7 would have been obvious	96
		9.	The dependent limitations of claim 8 would have been obvious	97
		10.	The dependent limitations of claim 9 would have been obvious	98
		11.	The dependent limitations of claim 10 would have been obvious	101
		12.	Conclusion	102
	C.		econdary Considerations Overcome <i>Prima Facie</i>	102
		1.	The formulations recited in the '462 patent produce no unexpected results	102
		2.	There was no long-felt but unmet need for the formulations recited in the '462 patent	103
		3.	There was no praise of the formulations recited in the '462 patent	104
		4.	There was no industry skepticism of the formulations recited in the '462 patent	105
X.	RES	ERVA	TION OF RIGHTS	105

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.